Study wrapper · #1296
Effects of Semaglutide versus Bariatric Surgery on Noninvasive Markers of Hepatic Steatosis and Fibrosis in Obesity with MASLD.
Editor's note
Single-center, prospective observational cohort with roughly 30 patients per arm, so groups were not randomized and baseline liver stiffness differed between them. The average semaglutide dose was about 1.0 mg weekly, below the 2.4 mg obesity dose, which makes the comparable stiffness reduction versus surgery more striking but also harder to generalize. Outcomes are non-invasive FibroScan and blood-score surrogates rather than biopsy or clinical endpoints. The authors themselves frame the weight-independent liver effect as hypothesis-generating.
Plain-language abstract
Researchers followed 92 adults with obesity and fatty liver disease for 72 weeks, comparing lifestyle changes alone, lifestyle plus semaglutide, and sleeve gastrectomy surgery. Both semaglutide and surgery improved scan-based markers of liver fat and stiffness, while lifestyle alone did little. Surgery produced far more weight loss, yet the drop in liver stiffness with semaglutide was similar and did not appear to depend on how much weight people lost.